Actavis Launches Topiramate In Four European Markets

Actavis has launched the antiepileptic drug Topiramate in the UK, Germany, France and Switzerland. The product was launched on day one as the originator’s patent expired on 25 September. Actavis was first to market in all four countries.

Topiramate is used to treat epilepsy and will be sold in tablets of 25mg, 50mg, 100mg and 200mg. Topiramate is the generic equivalent of Janssen-Cilaq’s Topamax / Epitomax.

Topiramate Actavis was developed by Actavis’ R&D in Iceland and in produced by Actavis in Hafnarfjordur, Iceland.

Actavis has already launched Topiramate in other countries where no patent protection was in place, including Portugal in 2007.

The Actavis Group develops, manufactures and sales generic pharmaceuticals. The company has development and manufacturing facilities in Europe, the US and Asia. The plants produce a variety of medicines in different formulations.